Podcasts about Efficacy

In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Eric L. Voorn discuss how exercise remains essential for people with neuromuscular disorders, even amid limited pharmaceutical options and safety concerns.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213781 https://www.sciencedirect.com/science/article/pii/S0960896625000458?via%3Dihub

Restez concentrés parce que ce n'est pas terminé! Après un premier épisode sur le diagnostic et la prise en charge non-pharmacologique du TDAH, on porte cette fois toute notre attention sur les pilules. Dans ce 46ème épisode du Pharmascope, Nicolas, Isabelle et leur invitée discutent donc du traitement pharmacologique du TDAH, plus spécifiquement des psychostimulants. Les objectifs pour cet épisode sont : Identifier les différentes formulations de psychostimulants disponibles dans le traitement du TDAH Comprendre les risques et les bénéfices associés à la prise de psychostimulants dans le traitement du TDAH Comparer l'efficacité et l'innocuité des différents psychostimulants entre eux en TDAH Ressources pertinentes en lien avec l'épisode Lignes directrices canadiennes CADDRA – Canadian ADHD Ressource Alliance : Lignes directrices canadiennes pour le TDAH, quatrième édition, Toronto (Ontario); CADDRA 2018. Lignes directrices américaines Wolraich ML et coll. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on children and adolescents with attention-deficit / hyperactive disorder. Pediatrics 2019. 144(4). pii:e20192528. Revues du TDAH Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-50. Auclair M, Elalami M. Traitement du TDAH chez l'enfant. Québec Pharmacie. Septembre 2018. 28p. Revues systématiques portant sur les mesures non-pharmacologiques Good AP et coll. Nonpharmacologic Treatments for Attention-Deficit / Hyperactivity Disorder: A Systematic Review. Pediatrics. 2018;141(6). Pii:e20180094. Lopez PL et coll. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018,23(3):CD010840. Études portant sur l'effet des amphétamines Punja S et coll. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev.2016;2:CD009996. Castells X et coll. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev.2018;8:CD007813. Études portant sur l'effet du méthylphénidate Storebo OJ et coll. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885. Epstein T et coll. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2014;9:CD005041. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073-86. Revue systématique globale  Stuhec M, Lukic P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019; 2:121-133. Liens utiles pour ressources Canadian ADHD Ressource Alliance (CADDRA). 2020. Centre for ADHD awareness, Canada (CADDAC). 2017. Clinique FOCUS. 2020. Annick Vincent. TDAH, informations, trucs et astuces. 2020.

Vous êtes toujours parmi nous? La fin approche! Dans ce 47ème épisode du Pharmascope et dernier de la série sur le TDAH, Nicolas, Isabelle et leur invitée discutent entre autres des options de traitement pharmacologiques autres que les psychostimulants. Les objectifs pour cet épisode sont : Comprendre les risques et les bénéfices associés à la prise de l'atomoxetine et de la guanfacine Évaluer la place de l'atomoxetine et la guanfacine dans l'algorithme de traitement du TDAH Adapter le traitement pharmacologique du TDAH en fonction du patient   Ressources pertinentes en lien avec l'épisode Lignes directrices canadiennes CADDRA – Canadian ADHD Ressource Alliance : Lignes directrices canadiennes pour le TDAH, quatrième édition, Toronto (Ontario); CADDRA 2018. Lignes directrices américaines Wolraich ML et coll. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Subcommittee on children and adolescents with attention-deficit / hyperactive disorder. Pediatrics 2019. 144(4). pii:e20192528. Revues du TDAH Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-50. Auclair M, Elalami M. Traitement du TDAH chez l'enfant. Québec Pharmacie. Septembre 2018. 28p. Revue systématique globale  Stuhec M, Lukic P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019; 2:121-133. Liens utiles pour ressources Canadian ADHD Ressource Alliance (CADDRA). 2020. Centre for ADHD awareness, Canada (CADDAC). 2017. Clinique FOCUS. 2020. Annick Vincent. TDAH, informations, trucs et astuces. 2020. Méta-analyse comparant l'atomoxétine aux psychostimulants en TDAH Liu Q, Zhang H, Fang Q, et coll. Comparative Efficacy and Safety of Methylphenidate and Atomoxetine for Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Meta-analysis Based on Head-To-Head Trials. J Clin Exp Neuropsychol. 2017; 39(9): 854-65. Évaluation de la guanfacine en TDAH par l'INESSS Institut national d'excellence en santé et services sociaux. INTUNIV XRMC – Trouble du déficit de l'attention avec ou sans hyperactivité. Février 2014. Étude portant sur des doses de 1 à 7mg de guanfacine en TDAH chez l'adolescent Wilens TE, Robertson B, Sikirica V, et coll. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2015;54(11):916–925.

You click on a link in an email—as one does. Suddenly you see a message from your organization, “You've been phished! Now you need some training!” What do you do next? If you're like most busy humans, you skip it and move on.Researcher Ariana Mirian (and co-authors Grant Ho, Elisa Luo, Khang Tong, Euyhyun Lee, Lin Liu, Christopher A. Longhurst, Christian Dameff, Stefan Savage, Geoffrey M. Voelker) uncovered similar results in their study “Understanding the Efficacy of Phishing Training in Practice.” The solution? Ariana suggests focusing on a more effective fix: designing safer systems.In the episode we talk about:Annual cybersecurity awareness training doesn't reduce the likelihood of clicking on phishing links, even if completed recently. Employees who finished training recently show similar phishing failure rates to those who completed it months ago. The study notes, “Employees who recently completed such training, which has significant focus on social engineering and phishing defenses, have similar phishing failure rates compared to other employees who completed awareness training many months ago.”Phishing simulations combined with training (where companies send out fake phishing emails to employees and, for those who click on the links, lead those employees through training) had little impact on whether participants would click phishing links in the future. Ariana was hopeful about interactive training but found that too few participants engaged with it to draw meaningful conclusions. The type of phishing lure (e.g., password reset vs. vacation policy change) influenced whether users clicked. Ariana warned that certain lures could artificially lower click rates.Ultimately, Ariana suggests focusing on designing safer systems—where the burden is taken off the end users. She recommends two-factor authentication, using phishing-resistant hardware keys (like YubiKeys), and blocking phishing emails before they reach users.This quote from the study stood out to me: “Our results suggest that organizations like ours should not expect training, as commonly deployed today, to substantially protect against phishing attacks—the magnitude of protection afforded is simply too small and employees remain susceptible even after repeated training.”This highlights the need for safer system design, especially for critical services like email, which—and this is important—inherently relies on users clicking links.Ariana Mirian is a senior security researcher at Censys. She completed her PhD at UC San Diego and co-authored the paper, “Understanding the Efficacy of Phishing Training in Practice.”G. Ho et al., "Understanding the Efficacy of Phishing Training in Practice," in 2025 IEEE Symposium on Security and Privacy (SP), San Francisco, CA, 2025, pp. 37-54, doi: 10.1109/SP61157.2025.00076.

Show SummaryOn today's episode, feature a conversation with Rear Admiral Terry Kraft, US Navy, Retired. Terry is the President and CEO of the USS Midway Museum, the longest-serving aircraft carrier int eh 20th Century that is now a museum in San Diego. Terry also serves on the board of directors for PsychArmor, and we talk about both of those roles in our conversation.  Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestRetired RADM Terry B. Kraft's military service spanned a remarkable 34-year Navy career highlighted by unparalleled leadership across diverse domains. As the son of a Navy captain, he graduated from the U.S. Naval Academy in 1981 and earned his designation as a Naval Flight Officer in 1982. His academic achievements include a master's degree in political science from Auburn University, a fellowship at Harvard's Kennedy School of Government, and graduation from the Navy Nuclear Power Program. Throughout his military service, RADM Kraft excelled in operational and strategic roles. He commanded aviation squadrons, ships, and a carrier strike group. As Executive Officer of the USS Theodore Roosevelt, he contributed to major operations including Desert Storm, Iraqi Freedom, and Enduring Freedom. His pivotal shore assignments included roles with VA-128, the Air Command and Staff College, U.S. Pacific Command, and the Chief of Naval Operations staff. His leadership in Maritime Aviation, Unmanned Aerial Systems, and Intelligence and Surveillance capabilities reflects his strategic vision and innovative approach. Additionally, he commanded the Navy Warfare Development Command and U.S. Naval Forces Japan, where he spearheaded critical initiatives to advance naval operations.After retiring from the Navy, Terry continued to demonstrate exceptional leadership in the private sector. From 2015 to 2023, he held senior management roles at General Atomics, driving technological and strategic advancements. Now, as President and CEO of the USS Midway Museum, he combines a commitment to preserving naval history with a passion for public education—values closely aligned with PsychArmor's mission. Terry and his wife, a fellow Navy veteran, reside in San Diego, where they enjoy attending music concerts and spending time with their children sailing around San Diego Bay. Links Mentioned During the EpisodeUSS Midway Museum WebsiteTerry's Bio on PsychArmorPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor Course, the Basics of Military Culture. Understand key values, customs, and experiences unique to service members and veterans through stories from six American service members. Perfect for employers, healthcare providers, and anyone working with military-connected individuals. You can find the resource here:  https://learn.psycharmor.org/courses/military-culture-series Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Dr. Justin Abbatemarco talks with Dr. Eric L. Voorn about the efficacy of combined personalized home-based aerobic exercise and coaching on physical fitness in people with neuromuscular diseases, compared with usual care.  Read the related article in Neurology®. Read the additional article that was referenced.  Disclosures can be found at Neurology.org. 

Optimiza tu LDL Colesterol e interpreta tu analítica o las de tus pacientes hoy, sin fármacos, aplicando estrategias nutricionales y suplementos clave con dosis y ciencia. Accede aquí:https://philhugo.com/producto/ldl-colesterol/  ¡Te espero dentro!Los suplementos be levels mencionados que formulo personalmente: Tu código de descuento: INTERGALACTICOBerberina: https://shop.belevels.com/products/berberine?sca_ref=745165.uf0cpcacla Omega 3: https://belevels.com/products/omega3?sca_ref=745165.uf0cpcaclaTriple Magnesio: https://belevels.com/products/magnesium?variant=47417739379012.uf0cpcacla Dosis y los demás explicados en el curso de Control Absoluto del LDL Colesterol.¿Sigues una dieta cetogénica estricta y tu LDL se ha disparado a niveles que asustarían a cualquier médico? No estás solo. En este episodio, desentrañamos la fisiología del Lean Mass Hyperresponder (LMHR): un perfil metabólico donde el colesterol LDL se eleva no por enfermedad, sino por eficiencia energética. Aprende cómo tu hígado, en ausencia de glucosa, convierte grasa en combustible a través de VLDL y LDL. Descubre por qué un LDL de 300 mg/dL puede ser normal si tu HDL está alto, tus triglicéridos bajos y tu inflamación es cero. Estudio a estudio, desmonto los miedos injustificados y propone estrategias clínicas reales para modular tu LDL si es necesario, desde el aumento de carbohidratos limpios hasta la optimización tiroidea y muscular. Este episodio no es para quien se conforma con los rangos de laboratorio estándar. Es para quien quiere entender su cuerpo desde la lógica metabólica y tomar decisiones con ciencia, no con miedo.ReferenciasApoB es biomarcador y posible diana terapéutica cardiovascular. Behbodikhah, Jennifer et al. “Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target.” Metabolites vol. 11,10 690. 8 Oct. 2021LDL sube mucho en "lean mass hyper-responders" con dieta baja en carbohidratos. Norwitz, Nicholas G et al. “Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a "Lean Mass Hyper-Responder" Phenotype.” Current developments in nutrition vol. 6,1 nzab144. 30 Nov. 2021Marcadores tiroideos y composición corporal predicen cambios en LDL con dieta cetogénica. Cooper, Isabella D et al. “Thyroid markers and body composition predict LDL-cholesterol change in lean healthy women on a ketogenic diet: experimental support for the lipid energy model.” Frontiers in endocrinology vol. 14 1326768. 21 Dec. 2023Omega-3 mejora dislipidemia en relación dosis-respuesta. Wang, Tianjiao et al. “Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials.” Journal of the American Heart Association vol. 12,11 (2023): e029512.Omega-3 de prescripción tiene efectos lipídicos beneficiosos. Bays, Harold E et al. “Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.” Expert review of cardiovascular therapy vol. 6,3 (2008): 391-409La berberina reduce lípidos, sola o combinada. Koppen, Laura M et al. “Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review.” Journal of evidence-based complementary & alternative medicine vol. 22,4 (2017): 956-968.Niacina baja lipoproteína(a) según fenotipo de apo(a). Artemeva, N V et al. “Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.” Atherosclerosis. Supplements vol. 18 (2015): 53-8

◆Voicy新チャンネル開設！【獣医Sara先生のペットの暮らしと健康】https://bit.ly/3sLljup【お知らせ

In this episode of the Diabetes Innovators Series, Rob interviews Dr. Viral N Shah discussing the Adjust T1D trial, which investigates the effects of semaglutide, a GLP-1 agonist, on adults with type 1 diabetes. The trial aims to explore adjunctive treatment options beyond insulin, focusing on improving glycemic control, weight loss, and overall patient outcomes. Dr. Shah shares insights on the trial's design, results, safety profile, and implications for future diabetes management, emphasizing the need for continued research and community support. Chapters 00:00 Introduction to the Adjust T1D Trial 03:06 Understanding Type 1 Diabetes and Treatment Options 05:46 Results of the Adjust T1D Trial 08:54 Safety and Efficacy of Semaglutide 11:45 Implications for Type 1 Diabetes Management 14:52 Future Research and Community Impact Resources: Dr. Viral Shah

In this episode, Dr. Jockers and Dr. Rob Bello dive into the science behind BPC-157 and why it's different from conventional anti-inflammatories like NSAIDs. You'll hear how this peptide works with your body—not against it—to speed healing and reduce chronic inflammation without halting the recovery process.   You'll also discover the power of stacking BPC-157 with TB-4 Frag, a synergistic combo known as the “Wolverine Stack.” Learn how this potent pair supports tissue repair, collagen production, angiogenesis, and even hormone receptor sensitivity for faster recovery and better performance.   Curious about dosing, delivery methods, or long-term safety? Dr. Bello shares insider insights on oral bioavailability, clinical outcomes, and what makes their formulations uniquely effective—especially for athletes, autoimmune patients, and anyone dealing with chronic pain.   In This Episode: 00:00 Introduction to Inflammation and BPC 03:23 Dr. Jocker's Personal Experience with BPC 157 04:33 Interview with Dr. Rob Bello: Peptides and BPC 157 04:55 The Origin and Benefits of BPC 157 09:48 BPC 157: Mechanisms and Healing Properties 20:14 BPC 157: Dosage and Administration 28:00 Understanding Lip Polysaccharides and Inflammation 28:23 Why Most New Year's Resolutions Fail 30:24 The Role of Endotoxin Labs in Autoimmune Treatment 31:30 Exploring TB 500 and Its Benefits 37:21 The Wolverine Stack: Enhancing Healing and Recovery 46:41 Ensuring Quality and Efficacy in Supplements 51:29 Conclusion and Final Thoughts     Support your heart, brain, and immune system with Paleo Valley's Wild Caught Fish Roe, a whole food source rich in Omega-3s like EPA and DHA. It's more bioavailable and stable than traditional fish oil, offering benefits for cardiovascular health, mood, and brain function. Go to paleovalley.com/jockers for 15% off your order!   Looking to boost your digestion, immunity, and energy? Just Thrive Probiotic is the answer! Unlike most probiotics that get destroyed by stomach acid, Just Thrive is clinically proven to reach your gut 100% alive. This means better digestion, improved immunity, enhanced energy, and easier weight management. Plus, with their industry-leading 100% money-back guarantee, you've got nothing to lose. Start feeling your best today, go to justthrivehealth.com and use code JOCKERS to save 20%.   Turn on your body's ability to heal with Vibrant Blue Oils, particularly their parasympathetic blend. These natural essential oils activate your nervous system, reduce inflammation, enhance digestion, detoxification, and improve brain function. Visit vibrantblueoils.com/jockers to grab a $15 full-size bottle of their Parasympathetic Blend today!"       "BPC-157 doesn't block inflammation. It empowers the healing process by regulating inflammation where it's needed." ~ Dr. Jockers     Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean  TuneIn Radio     Resources: Get 15% off Paleovalley Fish Roe: paleovalley.com/jockers – Use code JOCKERS Save 20% on Just Thrive: justthrivehealth.com – Use code JOCKERS Visit vibrantblueoils.com/jockers and save $15 on a full-size bottle today!       Connect with Dr. Rob Bello: Website: https://bellofamilychiropractic.com/   Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https:/www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/

Summary In this episode of the Future of Dermatology Podcast, Dr. Faranak Kamangar and Dr. Tina Bhutani discuss the latest advancements in dermatological treatments, focusing on the shift from traditional steroid-based therapies to innovative non-steroidal options. They explore the efficacy of new treatments, the importance of patient counseling, and the need for accessible and effective topical therapies. The conversation emphasizes the significance of setting realistic expectations for patients and the role of formulation in treatment success. Takeaways - The paradigm shift in dermatology is moving away from steroids to non-steroidal treatments. - Topical formulations must be elegant and user-friendly to ensure patient compliance. - Efficacy of new treatments can be seen as early as four weeks. - Setting low expectations can lead to higher patient satisfaction when results exceed them. - Patients often prioritize relief from itching over the appearance of their skin. - Non-steroidal treatments can be used safely on sensitive areas of the body. - Counseling patients on the use of medications can save time and improve outcomes. - Access to medications can be improved by documenting previous treatments. - The vehicle of a topical treatment is crucial for its effectiveness. - Investing in topical treatments is essential for the future of dermatology. Chapters 00:00 - Introduction to Dermatology Innovations 02:55 - The Shift from Steroids to Non-Steroidal Treatments 05:42 - Efficacy and Expectations in Treatment 08:42 - Patient Counseling and Treatment Compliance 11:41 - Access and Practical Considerations in Dermatology 14:38 - The Importance of Topical Treatments

Seja bem-vindo ao segundo episódio da série especial sobre lactoferrina, uma parceria entre o Ganep Educação e a Arese Pharma.Neste episódio, o Dr. Dan recebe a Dra. Zuleide, médica pediatra, para discutir o papel da lactoferrina desde os primeiros dias de vida até o desenvolvimento neurocognitivo da criança.

A recent systematic review in the journal Nutrients analyzed 146 studies to evaluate the safety and efficacy of glucosamine and chondroitin in humans. Researchers found that for conditions like osteoarthritis and joint pain, the supplements are generally effective and well-tolerated. Over 90% of the efficacy studies included in the review reported positive outcomes for patients. Similarly, a majority of safety studies (80 out of 107) concluded that the supplements have minimal to no adverse effects, with the most common being mild gastrointestinal complaints. The most frequently studied and effective daily dosages were 1500 mg for glucosamine and 1200 mg for chondroitin, typically taken together in two or three divided doses.Disclaimers:"This information is for educational purposes only and should not be interpreted as medical advice.""The information presented is from a systematic review of 146 human studies, the majority of which were randomized controlled trials.""Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, especially if you have a medical condition or are taking medications.""This channel does not provide medical advice."#Glucosamine #Chondroitin #Osteoarthritis #JointPain #SystematicReviewBaden KER, Hoeksema SL, Gibson N, Gadi DN, Craig E, Draime JA, Tubb SM, Chen AMH. The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review. Nutrients. 2025; 17(13):2093. https://doi.org/10.3390/nu17132093Glucosamine, Chondroitin, Glucosamine Chondroitin, Osteoarthritis, Joint Pain, Knee Osteoarthritis, Hip Osteoarthritis, Temporomandibular Disorder, Cartilage, Joint Health, Supplement Efficacy, Supplement Safety, WOMAC score, Lequesne Index, Visual Analog Scale, Joint Pain Relief, Anti-inflammatory supplements, Systematic Review, Human Studies, Clinical Trial, Glucosamine d

SummaryThis conversation explores various pressing issues in American politics, including the complexities of political bills, the role of lobbying, and the impact of gentrification on communities. It also delves into the effectiveness of protests in driving political change, the potential for civil unrest, and the future of international relations. Additionally, the discussion touches on the emerging role of cryptocurrency in modern finance and its implications for the housing market.TakeawaysPolitical bills should be concise and transparent.Lobbyists often write bills, compromising lawmakers' integrity.Child recovery operations highlight the importance of law enforcement.Gentrification displaces communities and alters demographics.Political violence is a growing concern in America.Protests may not lead to substantial change without strategic action.The future of governance may involve AI and technology.Cryptocurrency is becoming a significant asset in finance.International relations are shifting with changing alliances.The U.S. must adapt to new economic realities and challenges.Chapters00:00 The Call for Legislative Simplicity04:43 Child Recovery Operations and Law Enforcement's Role09:23 Gentrification and Its Impact on Black Communities13:50 The Efficacy of Protests and Political Violence21:58 The Future of Governance and Societal Order27:26 Natural Food Ingredients and Consumer Awareness29:56 Iranian Arrests and National Security Concerns31:11 Theater of War: Iran and U.S. Relations33:33 Proposals for Peace in the Middle East41:50 NATO and UN: The Future of Global Alliances54:16 Denuclearization and Global Stability56:21 The Rise of China and Economic Influence57:45 Military Industrial Complex and Domestic Defense01:00:34 The Need for a New Defense Strategy01:05:19 Perpetual Conflict and America's Future01:07:06 Bitcoin's Role in the Future Economy01:16:29 AI's Impact on Leadership and Governance

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode, Stephanie Boyles-Griffin, Jessica Tegt, Steve Demarais, and Bronson Strickland discuss the complexities of urban deer management, exploring the challenges posed by growing deer populations in urban areas. While recreational hunting remains the most effective and practical tool for population control in most settings, an increasing number of circumstances—especially in urban and suburban areas—render it unfeasible. Stephanie and Jessica, both from the Botstiber Institute, outline non-lethal and alternative methods commonly used to manage deer in these environments and walk through the series of decisions required to evaluate which techniques are appropriate and how likely they are to succeed.  Below, Stephanie and Jessica have provided resources if you are interested in learning more. Check out the MSU Deer Lab's online seminar series (here) and choose the Natural Resources option from the Categories drop down menu.  You will have to create an account to view the seminars.  The seminars are free unless you are seeking professional educational credits. Also, be sure to visit our YouTube channel (here)   Stephanie Boyles-Griffin: boylesgriffinadvisor@botstiber.org Jessica Tegt: jtegt@botstiber.org   Urban Deer Conflict Management Planning Resources https://www.humaneworld.org/sites/default/files/docs/HSUS%20Deer%20Conflict%20Mgt%20Plan_FINAL.pdf https://ecommons.cornell.edu/server/api/core/bitstreams/b297ac45-d908-4fd9-b06f-95cd5376907d/content https://www.fishwildlife.org/application/files/8816/1297/6730/Methods_for_Managing_Human-Deer_Conflicts_in_Urban_Suburban_and_Exurban_Areas.pdf   BIWFC https://wildlifefertilitycontrol.org/ https://digitalcommons.usu.edu/cgi/viewcontent.cgi?article=1871&context=hwi https://wildlifefertilitycontrol.org/webinars/webinar-surgical-solutions-innovations-in-nonlethal-deer-management/ https://wildlifefertilitycontrol.org/webinar-11-blacktail-deer/ https://wildlifefertilitycontrol.org/webinar-denicola/   Surgical https://www.whitebuffaloinc.org/ DeNicola, A. J., and V. L. DeNicola. 2021. Ovariectomy as a management technique for suburban deer populations. Wildlife Society Bulletin 45:445–455 Staten Island Story Map https://storymaps.arcgis.com/stories/e3a5f6d544594690a313693d1e88d9ef DeNicola, V., Mezzini, S., Bursać, P. et al. Effects of vasectomy on breeding-related movement and activity in free-ranging white-tailed deer. Mov Ecol 13, 34 (2025)   Nonsurgical Naugle, R. E., A. T. Rutberg, H. B. Underwood, J. W. Turner, Jr., and I. K. M. Liu. 2002. Field testing of immunocontraception on white-tailed deer (Odocoileus virginianus) at Fire Island National Seashore, New York, USA. Reproduction Supplement 60:143–153. Rutberg, A. T., R. E. Naugle, L. A. Thiele, and I. K. M. Liu. 2004. Effects of immunocontraception on a suburban population of white-tailed deer Odocoileus virginianus. Biological Conservation 116:243–250. Gionfriddo. J. P., A. J. DeNicola, L. Miller, and K. A. Fagerstone. 2011. Efficacy of GnRH immunocontraception of wild white-tailed deer in New Jersey. Wildlife Society Bulletin 35(3):149–160. Rutberg, A. T., R. E. Naugle, J. W. Turner, Jr., M. Fraker, D. Flanagan, and I. K. M. Liu. 2013. Tests of one-treatment immunocontraceptive vaccines on white-tailed deer (Odocoileus virginianus) on Fripp Island, SC. Wildlife Research 40:281–288. Walker, M.J., Shank, G.C., Stoskopf, M.K., Minter, L.J. and DePerno, C.S. (2021), Efficacy and Cost of GonaCon™ for Population Control in a Free-ranging White-tailed Deer Population. Wildl. Soc. Bull., 45: 589-596 

Grace Behind the GospelJune 29, 2025Introduction:Big Idea: Praise God's multidimensional grace behind the gospel!1. Incongruity of Grace—Humanity's Pervasive DepravityRom 3:9–18; Eph 2:1–32. Priority of Grace—The Father's Eternal ChoiceJohn 10:22–30; Eph 1:3–6; Rom 8:28–33; Acts 13:483. Superabundance of Grace—The Son's Specific Redemption Jn 6:35–40; 10:14–30; Rom 8:28–394. Efficacy of Grace—The Spirit's Decisive RegenerationJn 3:1–8; 6:41–44; Rom 8:28–30; Acts 16:11–155. Enduring Grace—The Trinity's Unconquerable PreservationJn 6:35–40; 10:22–30; Rom 8:28–30; Eph 1:13–14Conclusion:

In today's episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in pretreated patients with HER2-mutated non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine. In our exclusive interview, Dr Nagasaka discussed current second-line treatment standards for patients with HER2-mutated NSCLC, how the use of T-DXd in this setting may evolve with the emergence of investigational agents, and the importance of integrating HER2 immunohistochemistry testing into clinical practice.

Featuring an interview with Dr Patrick Y Wen, including the following topics: Glioma classification (0:00) Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50) Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55) Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46) Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30) Current and emergent strategies for the management of glioblastoma (31:27) Optimizing patient care and quality of life (46:24) CME information and select publications

Show SummaryOn today's episode, feature a conversation with Robin Kelleher, the CEO and co-founder of Hope For The Warriors, a national nonprofit dedicated to uplifting service members, veterans, and military families as they navigate the complexities of military life.   Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestRobin Kelleher is the CEO and co-founder of Hope For The Warriors®, a national nonprofit dedicated to uplifting service members, veterans, and military families as they navigate the complexities of military life. For 20 years, Robin has led HOPE with a unique blend of strategic insight and compassionate leadership. Through cultivating meaningful partnerships, driving the vision and impact of HOPE's mission across diverse communities, and building teams that deliver tangible outcomes, Robin has created countless opportunities to meet the evolving needs of our military families.Under her guidance, Hope For The Warriors has become a trusted voice in veteran and military family advocacy and a catalyst for restoring self, family, and hope within the military communityLinks Mentioned During the EpisodeHope For The Warriors WebsitePsychArmor Resource of the WeekThis week's resource of the week is the PsychArmor course Invisible Wounds at Home: Understanding Invisible Wounds. In this course, you will learn about four unseen wounds of military service, and be introduced to our series that includes specific courses on myths and facts about PTSD, Depression, TBI and Substance Use Disorder. You can find the resource here:  https://learn.psycharmor.org/courses/invisible-wounds-at-home-understanding-invisible-wounds Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In today's episode, supported by Coherus BioSciences, we had the pleasure of speaking with Michael Dennis, MD, about recent updates to the nasopharyngeal carcinoma treatment paradigm. Dr Dennis is a physician at Dana-Farber Cancer Institute; as well as an instructor in medicine at Harvard Medical School, both in Boston, Massachusetts. In our exclusive interview, Dr Dennis discussed the latest National Comprehensive Cancer Center guideline updates for the treatment of patients with nasopharyngeal carcinoma; practice-informing data from the phase 3 JUPITER-02 trial (NCT03581786), which investigated first-line toripalimab-tpzi (Loqtorzi) plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma; and ongoing developments in the locally advanced treatment setting.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CMF865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Moving the Efficacy NeedleWith Immunotherapy in Melanoma: Modern Standards and Next-Gen Strategies in Resectable and Unresectable Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and AIM at Melanoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Iovance Biotherapeutics.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CMF865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Moving the Efficacy NeedleWith Immunotherapy in Melanoma: Modern Standards and Next-Gen Strategies in Resectable and Unresectable Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and AIM at Melanoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Iovance Biotherapeutics.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CMF865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Moving the Efficacy NeedleWith Immunotherapy in Melanoma: Modern Standards and Next-Gen Strategies in Resectable and Unresectable Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and AIM at Melanoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Iovance Biotherapeutics.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CMF865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Moving the Efficacy NeedleWith Immunotherapy in Melanoma: Modern Standards and Next-Gen Strategies in Resectable and Unresectable Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and AIM at Melanoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb and Iovance Biotherapeutics.Disclosure information is available at the beginning of the video presentation.

Efficacy And Safety of AZD0780, An Oral Small Molecule PCSK9 Inhibitor For Treatment Of Hypercholesterolemia: Results From A Ph2b Randomized Placebo-controlled Clinical Trial

Stem Cell Therapy, Longevity & Regenerative Healing with Joshua Ketner Josh Ketner is a pioneer in the field of regenerative medicine. Josh is not only the insightful author of 'The Ultimate Guide to Stem Cell Therapy,' but he's also the visionary founder of Dream Body Clinic, nestled in tropical Puerto Vallarta, Mexico. At Dream Body Clinic, Josh and his team specialize in cutting-edge treatments like mesenchymal stem cell therapies, along with Human Growth Hormone (HGH) and other innovative age-defying medicines. In this powerful episode, we sit down with Joshua Ketner, founder of DreamBody Clinic in Mexico, to explore how stem cell therapy is transforming the future of health and longevity. Episode highlights: ✔ How stem cells work (hint: they're not what you think) ✔ Why patients are traveling to Mexico for affordable regenerative care ✔ Conditions treated: arthritis, autoimmune diseases, organ issues & more ✔ Success stories that defy the odds and how treatments can add quality years to your life. ✔ How hormone therapy & DNA methylation testing support anti-aging ✔ The truth about safety, U.S. regulations, and stem cell myths Chapters   06:23 Understanding Stem Cells, the sciene and Their Function 17:31 Common Conditions Treated at DreamBody Clinic 19:40 Addressing Skepticism and Success Stories 20:39 Treatment Process and Patient Experience 22:34 Safety and Side Effects of Treatments 30:27 Safety and Efficacy of Stem Cells in Cancer Treatment 33:26 Success Stories: Overcoming Autoimmune Conditions 36:55 Preventative Measures for Longevity 41:34 The Importance of Blood Work for Weight Loss 43:06 Understanding Treatment Costs and Transparency   This conversation breaks down complex science into actionable insights for anyone seeking pain relief, age reversal, and optimal health. Helpful links and resources: Learn about Dream Body Clinic https://www.youtube.com/@DBCStemCells Purchase Joshua's book here FB: facebook.com/dreambodyclinic IG: @clinicdreambody

Seth Diehl, our newest Ortho rep, joins me today to walk us through what makes the Ortho Molecular products exceptionally high quality and why they are our top choice. He explains how Ortho Molecular Products is the only remaining practitioner and supplement manufacturer and the only company that has not sold out. We also dive into our latest products, Choline Support, L-Theanine, Inositol Complex, Estro Support, Milk Thistle, and Neuro Support Magnesium. The benefits of combining L-Theanine with your morning coffee: It reduces the jittery caffeine excitement  It provides a relaxed energy boost It supports GABA, the most calming neurotransmitter Seth Diehl's Bio: Seth Diehl is an Account Executive with Ortho Molecular Products, proudly supporting healthcare practitioners throughout Iowa, including myself and the exceptional team at Integrative Health and Hormone Clinic.  Seth earned both his Bachelor's in Biology and Master's in Biomedical Sciences from Iowa State University. Initially unfamiliar with integrative and functional medicine, Seth quickly became an enthusiastic advocate after discovering the impactful role preventative approaches play in overall health.  Today, he combines his scientific expertise with a genuine passion for wellness, providing healthcare professionals with tailored health solutions and proactive patient care strategies. Seth feels privileged to collaborate with practitioners across his home state, backed by an organization that supports the transformation of the practice of medicine alongside integrative and functional medicine providers nationwide. In this episode: What differentiates Ortho Molecular Products from the rest, making them the best supplement manufacturer? How they use trademarked and patented raw materials throughout their product lines to ensure therapeutic outcomes Why you need to be careful when following the advice of influencers on social media- especially those with no background in healthcare  How Ortho Molecular Products safeguards its manufacturing processes by adhering to FDA regulations for its food and pharmaceutical products  How Choline Support supports cellular and mitochondrial membranes for better brain health and more energy How L-Theanine reduces stress and promotes relaxation without causing drowsiness How the unique form of magnesium in Neuro Magnesium Support improves sleep quality and memory and reduces brain fog How our new product, Inositol Complex, can be used to address the symptoms of PCOS How Estro Support helps women manage their menopause symptoms How Milk Thistle aids liver detoxification Links and Resources: Use code ENERGY to get 10% off ⁠⁠MITOCHONDRIAL COMPLEX Use code TURMERIC to get 10% off ⁠⁠TURMERIC Try Halo (Salt) Therapy for respiratory and skin health. Call 319-363-0033 to schedule your session. Relative Links for This Show: Neuro Magnesium Support  L-Theanine – 60 capsules Use code PODCAST for 10% off your next supplement purchase  Inositol Complex Choline Support EstroSupport Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

In part one of my in-depth conversation with Dr. Robin Carhart-Harris, we explore the political and cultural forces shaping the resurgence of psychedelic therapy. We critique the dominant psychiatric paradigm, which has long reduced mental illness to purely neurochemical dysfunction (leading to the rise of SSRIs), ignoring the psychological, social, and spiritual roots of psychological suffering. Carhart-Harris highlights how this narrow framework has failed to address rising rates of depression, PTSD, and OCD. We also discuss the historical reluctance of institutions like the NIH to fund psychedelic research, despite mounting evidence of its therapeutic potential. Under the previous leadership, psychedelic science was sidelined—but with new NIH leadership and a shifting political climate, there is fresh hope for meaningful support. The conversation emphasizes the need for a more holistic, integrative approach to mental health—one that values inner healing, human agency, and the transformative power of psychedelic experiences.Chapters:00:00 Introduction to Psychedelic Therapy12:48 The Political Landscape of Psychedelics19:12 The Shift in Mental Health Paradigms36:55 Understanding the Unique Power of Psychedelics48:38 Interconnectedness of Psychology, Biology, and Ethics56:11 Integration After Psychedelic Experiences01:04:10 Critique of NIH and Funding Challenges01:26:20 Psychedelics: Beyond Pharmacological Solutions01:31:35 Expectations and Their Impact on Therapy01:37:23 Efficacy and Side Effects of Psychedelic TherapyPodcast sponsors:1) Trinergy Health offers a 6-month program for mind-body recovery and wellness. Based on the foundational framework of Diet/trauma/toxins. To schedule an intake appointment, go to https://psychiatry2.com/schedule/ or call 262-955-6601. Use code Rav10 to get 10% discount for holistic psychiatry program.2) Alcami Elements - a natural, adaptogenic herbal supplement to kickstart your day!https://www.alcamielements.com/Receive 10% OFF first order or 30% OFF subscription order using code: ILLUSION This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

Show SummaryOn today's episode, we welcome back a previous guest, Marine Corps veteran Waco Hoover, an entrepreneur and investor with over 20 years of experience in venture capital, M&A, entertainment, media and live events. We talk about MCON, an annual event that celebrates military culture and includes MCON Health conducted in partnership with PsychArmor.  Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestWaco Hoover is an entrepreneur and investor with over 20 years of experience in venture capital, M&A, entertainment, media and live events.He served in the U.S. Marine Corps from 1997-2001 as an infantry Marine, combat water survival instructor and infantry scout. He served several deployments across Southeast Asia.After separation from the military, Hoover graduated from New York University, cum laude and completed Harvard Business School executive education programs. He then became an entrepreneur and investor who now has over 18 years of experience in venture capital, M&A, entertainment, media and live events.He is currently Chair of the Be The One initiative for the American Legion. He is also a co-owner of Veteran Entertainment Television, advisor to Founders Factory, a London based venture capital firm, Managing Partner at Xperiential Group, and serves on the board of Irreverent Warriors, a non-profit preventing veteran suicide. He has advised global brands including MGM Resorts, Informa, Vivendi, and Las Vegas Sands Corp. He was a co-founder and investor in businesses sold to Informa, Emerald, Endeavor Business Media and Onstream Media.Hoover speaks at industry events including VenuesNow, PTTOW!, CEMA, The American Legion, Military Influencer Conference, SXSW, Pollstar, TSE 100, Society for Independent Show Organizers, National Sports Forum and XLIVE.He lives in Southern California with his wife, son and two yellow labs, Tucker and Winnie. In his spare time, he enjoys surfing, diving, and mountaineering as often as possible. He is a member of The American Legion and recently hosted the Be the One Symposium at the 104th American Legion National Convention in Charlotte.Links Mentioned During the EpisodeMCON Web SiteMCON HealthPsychArmor Resource of the WeekThis week's resource of the week is the previous podcast episode featuring Waco, episode 156 where we talk about the American Legion's Be The One Campaign an initiative whose goal it is to eliminate the stigma related to mental health treatment, and in turn, lower the number of veterans who die by suicide every day.   You can find the resource here:  https://psycharmor.org/podcast/waco-hoover Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Efficacy and Safety of Xeligekimab in AS Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis GLP 1 Receptor Agonists in axSpA Patients

Efficacy and Safety of Xeligekimab in AS Sonelokimab in PsA Seronegative Arthritis Breakthroughs Novel Therapies in Axial Spondyloarthritis

Vaccines have become one of the most polarizing topics in public health, and frankly, for valid reasons. What we've witnessed over the past few years is an unprecedented breakdown in trust between medical institutions and the public - and that didn't happen in a vacuum.What is the truth about Vaccine Safety and Efficacy? Dr. Roger McFillin sits down with vaccine safety epidemiologist Allison Krug to expose the hidden forces shaping public health, from vaccine safety to the weaponization of fear. They dive deep into the failures of placebo-controlled trials, the truth about natural immunity vs. vaccine-induced immunity, and why good evidence is harder to find than you think. Allison shares what she learned working inside the pharmaceutical industry and reveals how mindset, belief systems, and disconnection from nature and spirituality are fueling today's chronic illness crisis. If you've ever questioned mainstream medicine or want to reclaim your health and autonomy, this conversation will change how you see the world.00:00 Introduction00:05:32 The Danger of Outsourcing Health to "Experts"00:20:45 Mindset, Pain, and the Illusion of Powerlessness00:42:49 Consciousness and the Healing Power Within01:05:32 Germ Theory, Genetics, and the Loss of Agency01:15:47 Awakening to Frequencies: A Spiritual Revolution01:22:23 Dark Spiritual Forces and the Battle for Consciousness01:31:27 How Public Schools Crush Creativity and Independence01:49:05 Medical Paradigm Flaws: What They're Not Telling You01:55:40 Spiritual Emptiness: The Hidden Cost of Modern Culture02:00:12 Radical Responsibility and the Return to Divine LoveAllision Krug WebsiteAllision Krug on XAllison Krug on Megyn Kelly COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities  Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

Efficacy and Safety of Xeligekimab in AS Who/When to Treat Clinically Suspect Arthralgia

Episode four of four on Paediatric ENT. Doctors Lisa and Sara are back with Paediatric Ear Nose and Throat Consultant Dr Simone Schaefer for this episode on nasal obstruction in children. We use examples of typical cases to discuss an approach to assessing these patients, discussing who ENT might want to see urgently, and differentials for these presentations. We discuss options for management in Primary Care and what ENT can do.    You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Efficacy and Safety of Nasal Steroids reference: Li Y, Xiong J, Zhang Z, Liao K, Zho X, Li J, Xiang J, Xu L. Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta-analysis. J Evid Based Med. 2024 Sep;17(3):626-642: https://pubmed.ncbi.nlm.nih.gov/39313999/ Safety of Intranasal Steroids link: McDonnell J, Weller K, Pien LC. Safety of Intranasal Steroids: an Updated Perspective. Curr Allergy Asthma Rep. 2020 Sep 7;20(11):69. https://pubmed.ncbi.nlm.nih.gov/32893309/ ENT UK Paediatric Snoring and Obstructive Sleep Apnoea in Children and Adolescents (accessed May 2025): https://www.entuk.org/_userfiles/pages/files/guidelines/global%20ent%20guidelines/global_health_guidelines_pediatric_snoring_obstructive_sleep_apnoea.pdf ENT UK Chronic Rhinosinusitis in Children: https://www.entuk.org/patients/conditions/64/chronic_rhinosinusitis_in_children/ NICE Clinical Knowledge Summaries Allergic Rhinitis (Jan 2024): https://cks.nice.org.uk/topics/allergic-rhinitis/ ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Show SummaryOn today's episode, we welcome back a previous guest Marine Corps Veteran and Veteran Advocate Dean Dauphinais. Dean is an enrolled member of the Turtle Mountain Band of Chippewa Indians, and was born and raised on the Spirit Lake Dakota Reservation in North Dakota. Dean and I talk about his work and his role on an advisory committee for PsychArmor to ensure cultural responsivity in content for Native and Tribal Veterans.  Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestDean Dauphinais served in the United States Marine Corps from 1995 to 1999 with 1st Battalion, 1st Marines, 1st Marine Division. He is the President and CEO of Native Eco Solutions, a consulting firm that has a goal of connecting tribal communities with opportunities to improve the quality of life of their people by inspiring collaboration in Indian Country and matching Indigenous values with strong business fundamentals in order to improve tribal communities·      Enrolled Member of the Turtle Mountain Band of Chippewa Indians·      Bachelor of Education degree - University of North Dakota·      AA Liberal Arts, Cankdeska Cikana Community College·      United States Marine Corps Veteran, Honorable Discharge·      National Congress of American Indians (NCAI), member·      California American Indian Business Chamber of Commerce, member·      Minnesota American Indian Chamber of Commerce, member·      Government Contract Consulting, Project Management, Community Organizing, Veterans Advocacy, Nonprofit Leadership& Management·      Strong network for collaborations in Indian Country, Veterans' Affairs and underserved communities Links Mentioned During the EpisodeDakota 38 FilmPsychArmor Resource of the WeekThis week's resource of the week is the previous two podcast episodes featuring Dean's colleagues on the PsychArmor American Indian and Alaska Native Advisory group, episode 214 with Dr. Chepa Rank and episode 220 with Retired Army Command Sergeant Major Julia Kelly.  You can find the resource here:  https://psycharmor.org/podcast/dr-melita-chepa-rank https://psycharmor.org/podcast/julia-kelly Episode Partner: This week's episode is brought to you by Humana, a leading health and well-being company that has joined forces with PsychArmor to develop campaigns and courses that support veterans and their families in achieving their best health. To learn more about how Humana honors and serves veterans visit healthequity.humana.com/veterans Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Send us a textIn this episode we talk with Dr. Riccardo De Giorgi about:His recently published study, "Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural monohydrate in depression: An 8-week pilot, double blind, randomised, placebo-controlled feasibility and exploratory, placebo-controlled feasibility and exploratory trial in an under-resourced area"Where he'd like to see additional research Dr Riccardo De Giorgi is Clinical Lecturer at the University of Oxford, Department of Psychiatry, and ST6 at Health Education England-Thames Valley, Oxford Health NHS Foundation Trust. He is interested in neuropsychopharmacology and evidence-based treatment of mental illness, especially mood disorders. He works on evidence synthesis, epidemiological, and experimental medicine studies to investigate repurposing opportunities for drugs with immuno-metabolic activity (e.g., statins, GLP1-RAs) in psychiatric disorders. Please note that this podcast is created strictly for educational purposes and should never be used for medical diagnosis or treatment.Connect w/ Dr. Riccardo Di GiorgiX: https://x.com/rdegiorgi?lang=enLinkedIn: https://uk.linkedin.com/in/riccardo-de-giorgi-59437b255Oxford: https://www.psych.ox.ac.uk/team/riccardo-de-giorgiMentioned:Creatine Monohydrate: https://amzn.to/449ZjveMORE NR New customers save 10% off all products on our website with the code NEWPOD10 If you would like to work with our practitioners, click here: https://nutritional-revolution.com/work-with-us/ Save 20% on all supplements at our trusted online source: https://us.fullscript.com/welcome/kchannell Join Nutritional Revolution's The Feed Club to get $20 off right away with an additional $20 Feed credit drop every 90 days.: https://thefeed.com/teams/nutritional-revolution If you're interested in sponsoring Nutritional Revolution Podcast, shoot us an email at nutritionalrev@gmail.com.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello in dismay examine the MAHA-Make America Health Again-report and its inclusion of fictious studies or “Creative literature degree Medical Science writing”, RFK Jr contradicted by the CDC for COVID-19 vaccine recommendations for children, reduction in MMR vaccine coverage, the ongoing bird flu and measles outbreaks, how the General Accounting Office instructed HHS to fix deficiencies in infectious disease testing before the next pandemic, before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections the Wasterwater Scan dashboard, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines approval of Moderna's mNEXSPIKE vaccine for fall 2025, childhood immunization recommendations for COVID-19 vaccines, where to find PEMGARDA, results from the phase 3 randomized clinical trial of pemivibart, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, the identification of an association between FOXP4 and long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode The MAHA report (The White House) White House Health Report Included Fake Citations (NY Times) C.D.C. Contradicts Kennedy and Keeps Advice That Children May Get Covid Shots (NY TImes) CDC revises recommendation for COVID vaccines in kids (CIDRAP) Exclusive: CDC Expert resigns from COVID vaccines advisory role (Reuters) Trends in County-Level MMR Vaccination Coverage in Children in the United States (JAMA Network) U.S. Cancels Contract With Moderna to Develop Bird Flu Vaccine (NY Times) Canada Wants to Kill 400 Ostriches. Kennedy and Dr. Oz Want to Save Them. (NY Times) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) H5 bird flu: current situation (CDC: Avian Influenza) Bird flu (CDC: Avian Influenza) H5N1 avian flu strikes another Arizona layer farm (CIDRAP) Bird flu outbreak kills 95% of Hickman's Arizona chickens, closes West Valley farms (AZCentral) Wastewater for measles (WasterWater Scan) Additional Denver Resident Tests Positive forMeasles (Denver: The Mile High City) Health officials alert public of potential measles exposure at Denver International Airport and nearby hotel (Colorado: Department of public health and environment) Colorado announces another measles case linked to Turkish Airlines flight (CIDRAP) Measles cases and outbreaks (CDC Rubeola) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Measles vaccine recommendations from NYP (jpg) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Public Health Preparedness: HHS Needs a Coordinated National Approach for Diagnostic Testing for Pandemic Threats (GAO: US Government Accountability Office) GAO to HHS: Fix ‘persistent deficiencies' in infectious-disease testing before next pandemic (CIDRAP) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (biRxiV) mNEXSPIKE is now approved and coming this fall (mNEXSPIKE) FDA approval for mNEXSPIKE (moderna) COVID-19 vaccine for 6 months, 12 years (CDC: childhood vaccination) COVID-19 vaccine for65 years and older (CDC: Adult vaccination) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices(ACIP)) Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19 (CID) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Genome-wide association study of long COVID (Nature Genetics) Reaching out to US house representative Letters read on TWiV 1224 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Stephen V. Liu, MD and Susan C. Scott, MD discuss advances in treating HER2-mutant lung cancer. Until recently, treatments for HER2-mutant lung cancer primarily involved chemotherapy, immunotherapy, and HER2-targeted therapies, with mixed results. Now, the treatment landscape of HER2-mutant lung cancer is changing.

Episode Overview: Dive into a thought-provoking episode where we explore the intricacies of the immune system, innovative natural remedies, and pressing global events. This episode is not just about the science of immunity but also touches on geopolitical tensions that are reshaping our world. Key Topics Discussed: 1. The Science and Efficacy of Coriolis Versicolor: Discover how this all-natural supplement is revolutionizing immune support for both humans and pets, as highlighted by over 400 studies from renowned institutions like Sloan-Kettering and Harvard University. 2. Predictive Programming – Fact or Fiction? The Supertramp Mystery: Unveil the eerie coincidences from historical media that hint at future events, exemplified by the symbolism in the 1979 Supertramp album "Breakfast in America." 3. Bioterror Threats and Global Repercussions: Analyze the recent revelations from Dr. David Martin about a possible forthcoming bioterror attack. How might this shape national security policies, and what are the implications for public health? Guest Appearance: Listen to insights from esteemed figures like Stephen Miller, who sheds light on the challenges in healthcare policies, and hear from Jeff, an advocate for natural immunological solutions effective against severe diseases. What to Expect: This episode offers a critical examination of contemporary issues, urging listeners to be informed and vigilant. With discussions ranging from immunity to looming geopolitical changes, it aims to empower the audience with knowledge to navigate these complex times. Call to Action: Stay proactive in safeguarding your health and communities. Consider immunity-boosting strategies from trusted sources and remain aware of unfolding global events that could impact your daily lives. Visit the recommended resources for more information. Thank you for Listening to Right on Radio. https://linktr.ee/RightonRadio Prayerfully consider supporting Right on Radio. Click Here for all links, Right on Community ROC, Podcast web links, Freebies, Products (healing mushrooms, EMP Protection) Social media, courses and more... https://linktr.ee/RightonRadio Live Right in the Real World! We talk God and Politics, Faith Based Broadcast News, views, Opinions and Attitudes We are Your News Now. Keep the Faith Here is the link to the document referenced. //efaidnbmnnnibpcajpcglclefindmkaj/https://biodefensecommission.org/wp-content/uploads/2024/05/National-Blueprint-for-Biodefense-2024_final_.pdf

Show SummaryOn today's episode, we're featuring a conversation with Navy Veteran Trinidad Aguirre, CEO and Co-Founder of VetsForever, a VA Accredited Law Group that supports veterans in obtaining disability ratings and discharge upgrades. We talk about the importance of finding support in accessing the benefits applications for the Department of Veterans Affairs. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestTrinidad Aguirre, a 100% disabled U.S. Navy Gulf War veteran, has excelled in both military and civilian careers. He is known for his hands-on leadership style and emotional intelligence, which he uses to build high-performing, collaborative teams. Integrity and innovation are the cornerstones of his leadership philosophy, which prioritizes mentorship, continuous improvement, and community impact. Throughout his career, he has demonstrated a steadfast commitment to providing top-tier legal services to the veteran community.He has held several executive board positions, including with the Hispanic Chamber of Commerce, as National President of Verizon's ERG Hispanic Support Organization, and as President of the American Marketing Association DFW. In addition, he has been at the forefront of change in the marketing industry, pushing for a greater emphasis on integrating awareness and advanced data analysis to effectively engage the desired target audience.A transformational leader driven by a passion for veteran advocacy, Trinidad has built a distinguished career dedicated to enhancing veterans' lives through financial security, mental health awareness, and strategic business excellence. He co-founded VetsForever (VF LLC), a 100% disabled veteran-owned organization. He leverages his two decades of dynamic experience in sales, marketing, and operational leadership to empower veterans to navigate the complexities of the VA claims process.Trinidad has implemented a proven, viable process for how VA-accredited organizations should approach the VA disability system. His primary mission focuses on delivering results within months rather than years, helping to meet veterans' urgent need for validation and economic support. The expedited process creates a safe space for veterans to improve and maintain their mental wellness. Financial security, in turn, provides the stability needed to sustain mental health, reinforcing his mission to integrate economic support with holistic veteran care.Trinidad is deeply committed to serving the community through his extensive involvement with nonprofit organizations such as OneTribe, Carry The Load, and the Stephen A Cohen Family Clinic. These organizations all concentrate on veterans' mental health, and Trinidad tirelessly supports through various initiatives that advocate for veterans and provide them with essential resources.Links Mentioned During the EpisodeVetsForever Web SitePsychArmor Resource of the WeekThis week's resource of the week is PsychArmor course, 15 Things Veteran Service Officers Want You to Know. This course aims to provide education about the role of Veterans Service Officers (VSOs) to make it easier for Veterans and their loved ones to navigate the benefits and claims process. We hope this course will encourage Veterans to work with a VSO to file claims for benefits, prevent continued misinformation about Veteran benefits and VSOs, and help Veterans recognize the importance of accessing the benefits they earned. You can find the resource here:  https://learn.psycharmor.org/courses/15-things-veterans-service-officers-want-you-to-know Episode Partner: This week's episode is brought to you by Humana, a leading health and well-being company that has joined forces with PsychArmor to develop campaigns and courses that support veterans and their families in achieving their best health. To learn more about how Humana honors and serves veterans visit healthequity.humana.com/veterans Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In this special episode of Skin Anarchy, Dr. Ekta Yadav is joined by Alicia Lindner, third-generation co-CEO of ANNEMARIE BÖRLIND, to explore how a family-founded skincare brand from Germany's Black Forest became a global benchmark for science-backed natural beauty. Alicia shares the origin story of her grandmother's bold philosophy—"If I can't eat it, I won't put it on my skin"—and how that ethos continues to define the brand nearly seven decades later.Listeners will get a behind-the-scenes look at how ANNEMARIE BÖRLIND blends traditional botanical knowledge with third-party clinical testing, delivering powerful results without compromising on sustainability. From sourcing pure deep spring water to refusing outside investors, the brand does everything with intention—including product development, which starts with a 15-woman R&D team and global inspiration.Discover the surprising success of their biodegradable hyaluronic acid eye patches, their cult-favorite overnight cream that changes texture through body heat, and why a complete skincare ritual still matters. Alicia also shares her views on financial sustainability, slow growth, and what it means to protect a legacy brand while innovating with purpose.Whether you're a skincare minimalist or a beauty deep-diver, this episode offers a powerful reminder that clean beauty doesn't have to choose between efficacy and integrity.Tune in to hear how ANNEMARIE BÖRLIND is setting a new standard for legacy beauty—one rooted in nature, backed by science, and built to last.CHAPTERS:(0:00) Introduction to AANNEMARIE BÖRLIND Skincare(1:06) The History of the Brand: From Grandmother to Third Generation(2:24) Keeping the Brand Relevant: Modernizing Legacy and Sustainability(4:03) Sustainability and Ingredient Sourcing(6:57) Brand Challenges: Maintaining Focus and Growth(8:21) The Importance of Product Development and Innovation(11:00) The Role of Science and Efficacy in Natural Skincare(13:02) Addressing Trends: The Rise of Eye Patches and Mask Products(26:24) Future Product Innovations and Closing ThoughtsTo learn more about ANNEMARIE BÖRLIND, visit their website and social media.Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

In this episode, Stephanie Boyles-Griffin, Jessica Tegt, Steve Demarais, and Bronson Strickland discuss the complexities of urban deer management, exploring the challenges posed by growing deer populations in urban areas. While recreational hunting remains the most effective and practical tool for population control in most settings, an increasing number of circumstances—especially in urban and suburban areas—render it unfeasible. Stephanie and Jessica, both from the Botstiber Institute, outline non-lethal and alternative methods commonly used to manage deer in these environments and walk through the series of decisions required to evaluate which techniques are appropriate and how likely they are to succeed.  Below, Stephanie and Jessica have provided resources if you are interested in learning more. Check out the MSU Deer Lab's online seminar series (here) and choose the Natural Resources option from the Categories drop down menu.  You will have to create an account to view the seminars.  The seminars are free unless you are seeking professional educational credits. Also, be sure to visit our YouTube channel (here)   Resources: Contact information Stephanie Boyles-Griffin: boylesgriffinadvisor@botstiber.org Jessica Tegt: jtegt@botstiber.org   Urban Deer Conflict Management Planning Resources   https://www.humaneworld.org/sites/default/files/docs/HSUS%20Deer%20Conflict%20Mgt%20Plan_FINAL.pdf https://ecommons.cornell.edu/server/api/core/bitstreams/b297ac45-d908-4fd9-b06f-95cd5376907d/content https://www.fishwildlife.org/application/files/8816/1297/6730/Methods_for_Managing_Human-Deer_Conflicts_in_Urban_Suburban_and_Exurban_Areas.pdf   BIWFC - https://wildlifefertilitycontrol.org/ - https://digitalcommons.usu.edu/cgi/viewcontent.cgi?article=1871&context=hwi - https://wildlifefertilitycontrol.org/webinars/webinar-surgical-solutions-innovations-in-nonlethal-deer-management/ - https://wildlifefertilitycontrol.org/webinar-11-blacktail-deer/ - https://wildlifefertilitycontrol.org/webinar-denicola/   Surgical - https://www.whitebuffaloinc.org/ - DeNicola, A. J., and V. L. DeNicola. 2021. Ovariectomy as a management technique for suburban deer populations. Wildlife Society Bulletin 45:445–455.   https://wildlife.onlinelibrary.wiley.com/doi/epdf/10.1002/wsb.1218 - Staten Island Story Map https://storymaps.arcgis.com/stories/e3a5f6d544594690a313693d1e88d9ef - DeNicola, V., Mezzini, S., Bursać, P. et al. Effects of vasectomy on breeding-related movement and activity in free-ranging white-tailed deer. Mov Ecol 13, 34 (2025). https://doi.org/10.1186/s40462-025-00554-5   Nonsurgical Naugle, R. E., A. T. Rutberg, H. B. Underwood, J. W. Turner, Jr., and I. K. M. Liu. 2002. Field testing of immunocontraception on white-tailed deer (Odocoileus virginianus) at Fire Island National Seashore, New York, USA. Reproduction Supplement 60:143–153. https://wildlifefertilitycontrol.org/wp-content/uploads/2002/01/Naugle-et-al-2002-Field-testing-of-immunocontraception-at-Fire-Island.pdf Rutberg, A. T., R. E. Naugle, L. A. Thiele, and I. K. M. Liu. 2004. Effects of immunocontraception on a suburban population of white-tailed deer Odocoileus virginianus. Biological Conservation 116:243–250. https://www.wildlifefertilitycontrol.org/wp-content/uploads/2019/02/Rutberg-et-al-2004-Biol-Cons-NIST.pdf Gionfriddo. J. P., A. J. DeNicola, L. Miller, and K. A. Fagerstone. 2011. Efficacy of GnRH immunocontraception of wild white-tailed deer in New Jersey. Wildlife Society Bulletin 35(3):149–160. Rutberg, A. T., R. E. Naugle, J. W. Turner, Jr., M. Fraker, D. Flanagan, and I. K. M. Liu. 2013. Tests of one-treatment immunocontraceptive vaccines on white-tailed deer (Odocoileus virginianus) on Fripp Island, SC. Wildlife Research 40:281–288. https://wildlifefertilitycontrol.org/wp-content/uploads/2013/06/Rutberg-et-al-2013-Wildlife-Research.pdf Walker, M.J., Shank, G.C., Stoskopf, M.K., Minter, L.J. and DePerno, C.S. (2021), Efficacy and Cost of GonaCon™ for Population Control in a Free-ranging White-tailed Deer Population. Wildl. Soc. Bull., 45: 589-596. https://doi.org/10.1002/wsb.1237 https://wildlife.onlinelibrary.wiley.com/doi/abs/10.1002/wsb.1237

We have the privilege to discuss 95 Theses on the Reformation of Football: Disputation on the Power and Efficacy of Global Football Governance with author, Dr David Kilpatrick. Over two parts we discuss the state of the sport, how we've come to adore it, and how to best preserve association football, or soccer. World Cups, Promotion & Relegation, Closed Systems, and Women's access to the sport are all covered. It's a long listen, but incredibly informative and full of ideas and opinions which might engage your intellectual mode.

In this episode of the Longevity Optimization Podcast, Dr. Carolina Reis Oliveira, co-founder and CEO of OneSkin, shares her journey in stem cell biology and the development of innovative products focused on skin and hair health. With a PhD in immunology and a background in stem cell and tissue engineering, Dr. Carolina leads OneSkin's research and development efforts to create molecules that target cellular aging, including the groundbreaking OS-01 peptide.OneSkin is a biotechnology company founded in 2016 and based in Silicon Valley, focused on developing anti-aging skin and hair products. Under Dr. Carolina Reis Oliveira's leadership, OneSkin aims to delay the onset of age-related diseases by targeting cellular aging mechanisms. Their flagship innovation, the OS-01 peptide, is scientifically designed to reduce senescent cells, promoting skin and hair health at a molecular level. The company combines cutting-edge research with practical applications to create products that support longevity and wellness.Save On OneSkin Hair Here: oneskin.co/KAYLALet's be friends!Instagram: https://www.instagram.com/kaylabarnes/?hl=enTikTok: https://www.tiktok.com/@femalelongevityX: https://x.com/femalelongevityWebsite: https://kaylabarnes.comJoin Female Longevity Community: https://kayla-barnes-lentz.circle.so/checkout/become-a-memberFollow One Skin:Instagram: https://www.instagram.com/oneskin.co/?hl=enTikTok: https://www.tiktok.com/@oneskin.coTimestamps00:00 Introduction to Longevity and Skin Health02:50 Understanding Hair Biology and Growth Phases07:00 Root Causes of Hair Loss10:10 Addressing Hair Loss: Diagnosis and Treatments12:03 Current Hair Loss Products and Their Limitations17:12 Innovative Solutions: OS1 Hair Product Development20:51 Clinical Study Results and Efficacy of Hair Treatments24:22 Combining Therapies for Optimal Hair Health25:03 Scalp Care and Hair Washing Practices28:24 Understanding Scalp Health and Microbiome33:55 Preventative Measures for Hair Loss39:57 Innovative Approaches to Hair Thinning46:18 The Science Behind Peptides and Hair Care

Contributor: Aaron Lessen, MD Educational Pearls: How do we take care of kids in severe pain? There are many non-pharmacologic options for pain (i.e. ice, elevation) as well as more conventional medication options (i.e. acetaminophen, NSAIDS) but in severe pain stronger medications might be indicated. These stronger medications include options such as IV morphine, a subdissociative dose of ketamine, as well as intranasal fentanyl. Intranasal fentanyl has many advantages: Studies have shown it might be more effective early on in controlling pain, as in the first 15-20 minutes after administration, and then becomes equivalent to other pain control options Total adverse effects were also lower with IN fentanyl, including low rates of nausea and vomiting To administer, use the IV formulation with an atomizer and spray into the nose; therefore, you do not need an IV line Dose is 1-2 micrograms per kilogram, can be redosed once at 10 minutes.  Don't forget about gabapentinoids for neuropathic pain, muscle relaxants for muscle spasms, and nerve blocks when appropriate. (Disclaimer: muscle relaxers have not been well studied in children) References Alsabri M, Hafez AH, Singer E, Elhady MM, Waqar M, Gill P. Efficacy and Safety of Intranasal Fentanyl in Pediatric Emergencies: A Systematic Review and Meta-analysis. Pediatr Emerg Care. 2024 Oct 1;40(10):748-752. doi: 10.1097/PEC.0000000000003187. Epub 2024 Apr 11. PMID: 38713846. Bailey B, Trottier ED. Managing Pediatric Pain in the Emergency Department. Paediatr Drugs. 2016 Aug;18(4):287-301. doi: 10.1007/s40272-016-0181-5. PMID: 27260499. Hadland SE, Agarwal R, Raman SR, Smith MJ, Bryl A, Michel J, Kelley-Quon LI, Raval MV, Renny MH, Larson-Steckler B, Wexelblatt S, Wilder RT, Flinn SK. Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline. Pediatrics. 2024 Sep 30:e2024068752. doi: 10.1542/peds.2024-068752. Epub ahead of print. PMID: 39344439. Summarized by Jeffrey Olson, MS4 | Edited by Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/

We have the privilege to discuss 95 Theses on the Reformation of Football: Disputation on the Power and Efficacy of Global Football Governance with author, Dr David Kilpatrick. Over two parts we discuss the state of the sport, how we've come to adore it, and how to best preserve association football, or soccer. World Cups, Promotion & Relegation, Closed Systems, and Women's access to the sport are all covered. It's a long listen, but incredibly informative and full of ideas and opinions which might engage your intellectual mode.

In this episode of Quah (Q & A), Sal, Adam & Justin answer four Pump Head questions drawn from last Sunday's Quah post on the @mindpumpmedia Instagram page.  Mind Pump Fit Tip: The 5 best diets for ANY goal. (1:38) The MOST common mistake people make with fitness & diet. (19:53) The BEST recovery tool to manage stress. (31:03) Terrible/harming tactics by mainstream media. (35:27) Creatine and depression. (41:27) The history of ginseng. (44:12) The conspiracy theory behind art. (48:36) Kids say the darndest things. (53:12) Mind Pump Recommends You Can't Ask That on Netflix. (56:21) Train the Trainer 3-Part Bonus Series dropping May 19th! (1:00:47) #Quah question #1 – What do you guys do to keep up strength when resting an injury? (1:01:37) #Quah question #2 – What should you do if you are reverse dieting but see weight gain? (1:04:17) #Quah question #3 – Will taking NSAID's to treat an acute injury completely negate gains from strength training? (1:06:04) #Quah question #4 – How do you see AI affecting the fitness industry? What are the pros and cons that can come of its involvement for trainers, nutrition coaches and their clients? (1:09:26) Related Links/Products Mentioned Visit Eight Sleep for an exclusive offer for Mind Pump Listeners! ** Use the code MINDPUMP to get $350 off your very own Pod 5 Ultra. The best part is that you still get 30 days to try it at home and return it if you don't like it - - Shipping to many countries worldwide. ** Visit Joy Mode for an exclusive offer for Mind Pump listeners! ** Enter MINDPUMP at checkout for 20% off your first order. ** May Special: MAPS 15 Performance or RGB Bundle 50% off! ** Code MAY50 at checkout ** Labs - Stephen Cabral Why Are Americans So Obsessed With Protein? Blame MAGA Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions Mind Pump #2530: Why All Women Should Take Creatine The history of ginseng in the management of erectile dysfunction in ancient China (3500-2600 BCE) Watch You Can't Ask That - Netflix Train the Trainer Webinar Series – 3 Part Bonus Series  Visit Hiya for an exclusive offer for Mind Pump listeners! ** Receive 50% off your first order ** Mechanisms and applications of the anti-inflammatory effects of photobiomodulation Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Mikhaila Peterson (@mikhailapeterson) Instagram Dr. Stephen Cabral (@stephencabral) Instagram Benjamin Bikman (@benbikmanphd) Instagram